Cargando…
Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity
Immunotherapies directly enhancing anti-tumor CD8(+) T cell responses have yielded measurable but limited success, highlighting the need for alternatives. Anti-tumor T cell responses critically depend on antigen presenting dendritic cells (DC), and enhancing mobilization, antigen loading and activat...
Autores principales: | Svensson-Arvelund, Judit, Cuadrado-Castano, Sara, Pantsulaia, Gvantsa, Kim, Kristy, Aleynick, Mark, Hammerich, Linda, Upadhyay, Ranjan, Yellin, Michael, Marsh, Henry, Oreper, Daniel, Jhunjhunwala, Suchit, Moussion, Christine, Merad, Miriam, Brown, Brian D., García-Sastre, Adolfo, Brody, Joshua D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684150/ https://www.ncbi.nlm.nih.gov/pubmed/36418317 http://dx.doi.org/10.1038/s41467-022-34791-8 |
Ejemplares similares
-
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming
por: Aleynick, Mark, et al.
Publicado: (2023) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012) -
Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022) -
Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023) -
Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)